3 Long-term Income Plays: Legal And General Group Plc, GlaxoSmithKline Plc And SSE PLC

Legal & General Group Plc (LON: LGEN), GlaxoSmithKline Plc (LON: GSK) and SSE PLC (LON: SSE) will bring joy to long-term income seekers, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Share price growth can give investors a real buzz in the short-term, but it’s the dividend income that brings the most satisfying long-term rewards. If you can generate 4% or 5% a year and use that to buy more shares in the same company, eventually you will be talking real money.

Up to three-quarters of your long-term returns will come from dividend income. The key phrase here is long-term. Here are three income stocks with staying power.

Legal & General Group

Over the last five years, FTSE-listed insurance giant Legal & General Group (LSE: LGEN) has doubled your money in share price growth alone. The last year has been stickier with the stock down 15%, but that won’t worry long-term income seekers, as L&G currently yields 5.62%. In fact, it works in their favour, because if they re-invest their dividends they’ll pick up more stock at the lower price.

Somebody who invested five years ago, when the stock traded at 116p (against 238p today), is effectively getting a yield of 11.5% on their original investment. FTSE insurers have all been hit by wider stock market uncertainty yet L&G still has plenty in its favour, as a major presence in three fast-growing areas: low-cost tracker funds, UK workplace auto-enrolment schemes and bulk annuities. Earnings per share (EPS) are forecast to rise 7% this year and 8% in 2016, when the yield is expected to hit an even juicier 6.4%.

GlaxoSmithKline

Investment fashions change but one thing seems eternal: pharmaceutical giant GlaxoSmithKline (LON: GSK) is still the FTSE 100 poster boy for dividend income. Yet even dividend heroes can suffer their moments of misfortune, with the Chinese bribery scandal and more importantly, fears of a patent cliff, hitting investor sentiment. Glaxo has been trying to wean itself off its dependence on respiratory treatment Advair/Seretide, with sales down sharply on generic competition. Moves to diversify into vaccines and consumer health, pharmaceutical products and the HIV franchise, are finally bearing fruit.

Four years of negative EPS are expected to turn positive with a vengeance in 2016, rising 14%. Forecast dividend growth looks less spectacular, but the yield is expected to continue hovering around 5.4%, perfect for investors who like to play the long game.

SSE

Some may think I’m rash by including utility company SSE (LSE: SSE) under the heading “long-term income plays”. Its dividend may yield a juicy 5.83% but there has been talk of a cut as cover gets stretched. SSE has been hit by falling energy prices and increased retail market competition, as disgruntled customers switch from the Big Six energy companies to smaller challengers.

Management has committed to raising its dividend by RPI inflation at least, a commitment it stands by even though EPS are expected to fall from 124.1p in the year to March 2015 to 111.79p this year, a drop of almost 10%. It also warned that dividend cover could range from around 1.2 times to around 1.4 times over the next three years, but the yield is still forecast to hit 6% by March 2018, suggesting fears of a cut are overplayed. It still has its believers: JP Morgan is overweight with a target price of 1,550p, only slightly above today’s 1,515p. That confirms my view: forget growth, SSE is all about the income, and the income is good.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Down 45% in 5 years, this UK stock now offers a stunning 11% dividend yield!

Among the highest UK dividend yields, one immediately begs for closer inspection. Can this double-digit marvel really pull it off?

Read more »

Middle-aged black male working at home desk
Investing Articles

Here’s how Aviva shares could soon rise a further 20%… or fall 15%!

Aviva shares have fallen back a bit, with Q1 results due in May. But analysts are mostly optimistic, and see…

Read more »

Dominos delivery man on skateboard holding pizza boxes
Investing Articles

£5,000 invested in high-yield FTSE 250 stock Domino’s Pizza on 7 April is now worth…

Anyone who put £5,000 into FTSE stock Domino’s Pizza after the Easter break would now be laughing as its share…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

Tesla stock’s up 50% in a year. Could it go even higher?

This week saw Tesla announce mixed first-quarter results. Yet Tesla stock's worth half as much again as a year ago.…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

Up 9% today, is this FTSE 250 share’s recovery gaining pace?

This FTSE 250 share has had a welcome boost in the market today after it unveiled an upbeat trading statement.…

Read more »

Lady wearing a head scarf looks over pages on company financials
Investing Articles

5 years ago Barclays shares cost just 181p! Are they still a buy at today’s 434p?

Harvey Jones says investors have to pay a lot more to buy Barclays shares than just a few years ago,…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Up 36%, could Shell shares still offer value for the long term?

Christopher Ruane has owned Shell shares before -- and got burnt by a dividend cut. Could recent oil price rises…

Read more »

A young Asian woman holding up her index finger
Investing Articles

£5,000 invested in FTSE 100 stock London Stock Exchange Group 1 month ago is now worth…

FTSE 100 powerhouse London Stock Exchange Group has been dragged into the software sell-off. However, recently, it has started to…

Read more »